Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB-0,25
PKN96,4696,62,33
Msft-1,16
Nokia4,7464,792,40
IBM-0,76
Daimler AG47,4247,435-0,17
PFE0,49
21.09.2019 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.09.2019
Futura Medical (FUM.L, London)
Závěr k 20.9.2019 Změna (%) Změna (GBP) Objem obchodů (GBP)
0,325 1,56 0,01 424 175
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 23.09.2019
Popis společnosti
Obecné informace
Název společnostiFutura Medical plc.
TickerFUM
Kmenové akcie:Ordinary Shares
RICFUM.L
ISINGB0033278473
Poslední známé roční výsledky31.12.2018
Poslední známé čtvrtletní výsledky31.12.2018
Počet zaměstnanců k 31.12.2018 15
Akcie v oběhu k 01.02.2019 204 660 267
MěnaGBP
Kontaktní informace
Ulice40 Surrey Technology Centre, Occam Road
MěstoGUILDFORD
PSČGU2 7YG
ZeměUnited Kingdom
Kontatní osobaJames Barder
Funkce kontaktní osobyChief Executive Officer, Executive Director
Telefon441 483 685 670
Fax441483685671
Kontatní telefon4401 483 685 670

Business Summary: Futura Medical plc is a United Kingdom-based pharmaceutical company that develops products for consumer healthcare. The Company is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin. It specializes in sexual health and pain relief, and has approximately five products in its development pipeline, which include CSD500, MED2002, TPR100, TIB200 and SPR300. Its CSD500 product incorporates an erectogenic gel (known as Zanifil gel) to help men maintain a firmer erection during intercourse whilst wearing a condom. Its MED2002 is a gel applied directly to the penis for the treatment of male erectile dysfunction (ED). The Company's TPR100 is a gel to provide pain relief. Its SPR300 is a gel, which combines methyl salicylate and menthol with the DermaSys delivery system.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2018, Futura Medical plc. revenues decreased from L363K to L0K. Net loss increased 51% to L5.9M. Revenues reflect Europe segment decrease from L350K to L0K, Middle East segment decrease from L13K to L0K. Higher net loss reflects Research and development costs increase of 47% to L6M (expense), Administrative costs increase of 10% to L1.2M (expense).
Odvětvová klasifikace
TRBC2012Generic Pharmaceuticals
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations



  • Poslední aktualizace: 23.09.2019
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorJames Barder50
Executive Director, Head of R&DKen James6316.11.201616.11.2016